Tag Archives: EMD Serono

October, 2018

3 October
Accelerated Cure Project Collaborates with EMD Serono to Advance Patient-Focused Drug Development in Multiple Sclerosis

WALTHAM, Mass., Oct. 2, 2018 /PRNewswire/ — Accelerated Cure Project (ACP) for Multiple Sclerosis (MS) today announced it has entered into a ground-breaking collaboration with EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, to capture and integrate the perspectives of people affected by …
Share

27 December
HTG Molecular Diagnostics Expands Collaboration with Merck KGaA

TUCSON, Ariz. and DARMSTADT, Germany, Dec. 26, 2017 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications today announced a new Master Collaboration Agreement for translational programs with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The Master Collaboration …
Share

9 May
FDA Approves Pfizer’s Bavencio for Treatment of Patients with Advanced Bladder Cancer

ROCKLAND, Mass. and NEW YORK, May 9, 2017 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection for the treatment of patients …
Share

30 November
FDA Grants Priority Review to Avelumab for Treatment of Merkel Cell Carcinoma

EMD Serono Inc., the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono’s Biologics License Application (BLA) for avelumab. This review relates to avelumab’s proposed …
Share

2 March
Merck KGaA Initiates Phase 3 Study of its Humira Biosimilar

DARMSTADT, Germany, March 2, 2016 /PRNewswire/ — Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the initiation of a global phase III clinical study of MSB11022, a proposed biosimilar of adalimumab, in chronic plaque psoriasis. This milestone is a strong reflection of Merck KGaA, Darmstadt, Germany’s progress …
Share

12 May
FDA Fast Tracks Merck KGaA’s Pancreatic Cancer Candidate

The US Food and Drug Administration (FDA) has granted Fast Track designation to Merck KGaA and partner Threshold Pharmaceuticals’ investigational pancreatic cancer drug. The companies won Fast Track status for the development of evofosfamide, administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally …
Share